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Background
The immunoregulatory enzyme indoleamine 2,3-dioxygenase, which catalyzes the conversion
of tryptophan into kynurenine, is expressed in a significant subset of patients with acute
myeloid leukemia, resulting in the inhibition of T-cell proliferation and the induction of regu-
latory T cells. Acute myeloid leukemia cells can be differentiated into dendritic cells, which
have increased immunogenicity and have been proposed as vaccines against leukemia.
Design and Methods
Leukemic dendritic cells were generated from acute myeloid leukemia cells and used as stimu-
lators in functional assays, including the induction of regulatory T cells. Indoleamine 2,3-dioxy-
genase expression in leukemic dendritic cells was evaluated at molecular, protein and enzymat-
ic levels. 
Results
We demonstrate that, after differentiation into dendritic cells, both indoleamine 2,3-dioxyge-
nase-negative and indoleamine 2,3-dioxygenase-positive acute myeloid leukemia samples
show induction and up-regulation of indoleamine 2,3-dioxygenase gene and protein, respec-
tively. Indoleamine 2,3-dioxygenase-positive acute myeloid leukemia dendritic cells catabolize
tryptophan into kynurenine metabolite and inhibit T-cell proliferation through an indoleamine
2,3-dioxygenase-dependent mechanism. Moreover, indoleamine 2,3-dioxygenase-positive
leukemic dendritic cells increase the number of allogeneic and autologous CD4+CD25+ Foxp3+
T cells and this effect is completely abrogated by the indoleamine 2,3-dioxygenase-inhibitor, 1-
methyl tryptophan. Purified CD4+CD25+ T cells obtained from co-culture with indoleamine
2,3-dioxygenase-positive leukemic dendritic cells act as regulatory T cells as they inhibit naive
T-cell proliferation and impair the complete maturation of normal dendritic cells. Importantly,
leukemic dendritic cell-induced regulatory T cells are capable of in vitro suppression of a
leukemia-specific T cell-mediated immune response, directed against the leukemia-associated
antigen , Wilms’ tumor protein.  
Conclusions
These data identify indoleamine 2,3-dioxygenase-mediated catabolism as a tolerogenic mech-
anism exerted by  leukemic dendritic cells and have clinical implications for the use of these
cells for active immunotherapy of leukemia.
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Citation: Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D, Evangelisti C,
Rutella S, De Cristofaro R, Ottaviani E, Baccarani M, and Lemoli RM. Indoleamine 2,3-dioxyge-
nase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing
potent T regulatory cells. Haematologica 2010;95(12):2022-2030.
doi:10.3324/haematol.2010.025924
©2010 Ferrata Storti Foundation. This is an open-access paper. 
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a
leukemia-specific immune response by inducing potent T regulatory cells
Antonio Curti,1 Sara Trabanelli,1 Chiara Onofri,1 Michela Aluigi,1 Valentina Salvestrini,1 Darina Ocadlikova,1
Cecilia Evangelisti,1 Sergio Rutella,2,3 Raimondo De Cristofaro,4 Emanuela Ottaviani,1 Michele Baccarani,1
and Roberto M. Lemoli1
1Department of Hematology and Oncological Sciences “L. and A. Seràgnoli”, Institute  of Hematology and Medical Oncology 
“L. and A. Seràgnoli”, University of Bologna and Stem Cell Center, Azienda Ospedaliero-Universitaria, Bologna, Italy; 
2Department of Hematology, Catholic University Medical School, Rome, Italy; 3IRCCS San Raffaele Pisana, Rome, Italy, 
and 4Department of Medicine and Geriatrics, Hemostasis Research Center, Catholic University Medical School, Rome, Italy   
ABSTRACT
2022 haematologica | 2010; 95(12)
©F
err
ata
St
rti 
Fo
un
da
tio
n
Introduction
Indoleamine 2,3-dioxygenase (IDO1) is a key enzyme
in tryptophan metabolism, catalyzing the initial rate-lim-
iting step of tryptophan degradation along the kynure-
nine pathway.1 Tryptophan starvation by IDO1 con-
sumption inhibits T-cell activation,1,2 while products of
tryptophan catabolism, such as kynurenine derivatives
and oxygen free radicals, negatively regulate T-cell prolif-
eration and survival.1,3 More recently, IDO1-expressing
cells, including dendritic cells (DC), have been demon-
strated to have a tolerogenic effect on T-cell-based adap-
tive immune response by expanding/inducing a popula-
tion of regulatory T cells (Treg).4-6 Interestingly, human
monocyte-derived DC have recently been demonstrated
to induce a population of Treg in both allogeneic and
autologous culture systems.7,8 
A wide variety of human solid tumors express IDO1.9
We and others have also demonstrated that acute
myeloid leukemia (AML) cells express an active IDO1
protein, which converts tryptophan into kynurenine and
inhibits allogeneic T-cell proliferation.10-13 Moreover, we
demonstrated that modulation of tryptophan catabolism
by AML cells results in the de novo induction of Treg by
conversion from CD4+CD25– naïve T cells.14
AML samples have been used to generate, in vitro, DC-
like cells (AML-DC) which stimulate T-cell proliferation
and cytotoxic T lymphocyte activity against autologous
leukemia cells more efficiently than undifferentiated
blasts.15-18 Thus, AML-DC have been proposed for use as
a cellular vaccine in leukemia patients for the treatment
of minimal residual disease.19 However, we previously
demonstrated that AML-DC are not fully competent to
revert T-cell impairment induced by the leukemic
microenvironment,20 and it remains to be elucidated
whether AML-DC retain some intrinsic tolerogenic fea-
tures, including the capacity of inducing Tregs. To this end,
in the present study, we tested the expression of IDO1
by AML-DC and the functional role of this enzyme in
the development of Treg cells.
Design and Methods
Cells
Buffy coats were obtained during the preparation of transfu-
sion products from healthy adults. Peripheral blood samples
including at least 70% leukemic cells were harvested from
AML patients at diagnosis and used for AML-DC generation.
Normal and leukemic mononuclear cells were obtained by gra-
dient centrifugation (Lymphoprep; 1.077 g/mL; Nycomed
Pharma, Oslo, Norway). CD14+, CD3+, CD8+ and CD4+ cells
were purified from the mononuclear cell fraction in a
MiniMacs high-gradient magnetic separation column (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the manu-
facturer’s instructions (the purity of cell populations was
always greater than 95%). CD4+CD25+ and CD4+CD25- cells
were isolated using a MiniMacs CD4+CD25+ regulatory T-cell
isolation kit (Miltenyi) according to the manufacturer’s instruc-
tions. To achieve the highest possible purity, positive and neg-
ative cell fractions were separated over a second column.
CD4+CD25+ cells routinely accounted for more than 90% of
total cells, as evaluated by flow activated cell sorting analysis.
CD4+CD25– T cells accounted for more than 98% of the cells
collected in the negative fraction. 
Generation and maturation of leukemic dendritic cells 
AML-DC were derived from AML blasts of monocytic lineage,
which are known to give rise to AML-DC more efficiently.17
However, similar results were also obtained with AML cells of lin-
eages other than monocytic (Online Supplementary Table S1). AML-
DC were generated from eight patients with AML. Briefly, 106/mL
AML blasts were cultured for 6 days in RPMI 1640 (Whittaker
Biproducts, Walkersville, MD, USA), supplemented with 10%
fetal calf serum (Sera Lab, Sussex, UK), antibiotics, L-glutamine,
HEPES buffer (Whittaker Biproducts), and non-essential amino
acids (Whittaker Biproducts), hereafter referred as complete medi-
um, 50 ng/mL granulocyte-macrophage colony-stimulating factor
(Endogen, Woburn, MA, USA), 800 U/mL interleukin (IL)-4
(Endogen) and 10 ng/mL tumor necrosis factor-α (Endogen). For
final maturation, day 6 AML-DC (immature DC) were resuspend-
ed at a density of 106 cells/mL in complete medium plus granulo-
cyte-macrophage colony-stimulating factor (50 ng/mL), IL-4 (800
U/mL), tumor necrosis factor-α (10 ng/mL), IL-6 (Endogen;10
ng/mL), IL-1-β (Endogen; 10 ng/mL), and prostaglandin E2
(Endogen; 1 mg/mL) and incubated for 48 h (mature DC). The
same protocol was followed to generate and mature normal DC
obtained from highly purified CD14+ cells, as previously report-
ed.21 The generation of functionally active AML-DC was assessed
by phase-contrast microscopy, immunophenotyping and mixed
lymphocyte reaction. 
Construction of the standard curve for absolute 
quantification of IDO1 transcript
To create a standard curve for the absolute quantification of
IDO1 gene transcript copy number, the polymerase chain reaction
product obtained by amplification with the following forward and
reverse primers (forward: 5’-ACA GAC CAC AAG TCA CAG
CG-3’; reverse: 5’-AAC TGA GCA GCA TGT CCT CC-3’) of
cDNA from human placenta (Clontech, BD Biosciences Italia) was
cloned into the pCR2.1-TOPO vector using a TOPO TA cloning
kit (Invitrogen, Carlsbad, CA, USA). Serial 10-fold dilutions of the
plasmid from 105 to 100 plasmid copies were prepared and used to
create the standard curve of IDO transcript. The standard curve for
ABL transcript was obtained using FusionQuant plasmid standards
commercially available from Ipsogen (Ipsogen, New Haven, CT,
USA), starting from 105 and ending at 103 plasmid copies.
Real-time quantitative polymerase chain reaction
analysis of IDO1
Quantitative polymerase chain reaction amplification was per-
formed with an ABI-PRISM 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). The reaction was per-
formed in a final volume of 25 mL, consisting of 5 mL cDNA (diluted
1:3) or plasmid, 12.5 mL of TaqMan Universal PCR Master Mix
(Applied Biosystems), 0.75 mM primers plus 1 mM probe specific
for IDO1 (forward: 5’-GGT CAT GGA GAT GTC CGT AA-3’,
reverse: 5’-ACC AAT AGA GAG ACC AGG AAG AA-3’, probe:
5’-6-FAM-CTG TTC CTT ACT GCC AAC TCT CCA AGA AAC
TG-TAMRA-3’)7 and 0.37 mM primers plus 1.2 mM probe specific
for ABL (forward: 5’-TGG AGA TAA CAC TCT AAG CAT AAC
TAA AGG T-3’; reverse: 5’ GAT GTA GTT GCT TGG GAC CCA-
3’; probe: 5’ FAM-CCA TTT TTG GTT TGG GCT TCA CAC
CAT T-TAMRA-3’). The quantitative polymerase chain reaction
conditions consisted of an initial step at 50°C for 2 min, a denatu-
ration step at 95°C for 10 min, followed by 40 cycles, each for 15
s at 95°C and 1 min at 60°C.22 Absolute quantification of the tran-
script copy number was achieved for the IDO1 and ABL genes
from the corresponding standard curves. Results were expressed as
a ratio: (IDO1 copy number/ABL copy number)x104. All real-time
polymerase chain reactions were performed at least in triplicate.
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IDO1 expression and activity
AML cells were tested for IDO1 expression both at mRNA
and protein levels. Polymerase chain reaction analysis of human
IDO1 was performed as described above. For detection of IDO1
protein, rabbit anti-human IDO1 polyclonal antibody (Alexis
Biochemicals, NY, USA) was used. Western blot analysis was
performed as previously reported.23 Serum concentrations of
kynurenine and tryptophan were quantified using reversed-
phase high performance liquid chromatography. The chromato-
graphic procedure was similar to a method previously described,
with minor modifications.24 In brief, sample aliquots (100 mL)
were de-proteinized with HClO4 (0.3 M final concentration).
After centrifugation (14000 rpm for 15 min), the supernatants
were spiked with 50 µM 3-L-nitrotyrosine and analyzed using a
ReproSil-Pur C18-AQ (4x250 mm, 5 mm granulometry) reversed-
phase high performance liquid chromatography column (Dr.
Maisch GmbH, Ammerbuch-Entringen, Germany), using a dou-
ble-pump mod. 2080 HPLC apparatus from Jasco (Tokyo, Japan)
equipped with a model 2070 UV spectrophotometric detector
and a FP-2020 fluorescence detector. Both detectors were con-
nected in series to allow simultaneous measurements. The chro-
matographic peaks were detected by recording UV absorbance
at 360 nm and emission fluorescence at 366 nm, after excitation
at 286 nm. The elution solvent was 2.7% CH3CN in 15 mM
acetate buffer, pH 4.0 (both reversed-phase high performance
liquid chromatography-grade from Fluka, Milan, Italy). Borwin
1.5 and MS Excel software were used to control the set-up and
for peak quantification. The concentrations of components were
calculated according to peak heights and were compared with
both 3-nitro-l-tyrosine as the internal standard and the reference
curves constructed with genuine kynurenine and L-trypthophan,
both purchased from Sigma-Aldrich (St. Louis, MO, USA).
Induction of allogeneic and autologous regulatory 
T cells by leukemic dendritic cells 
AML-DC (105/mL) were cultured in complete medium with
106/mL allogeneic or autologous CD3+ T cells for 7 days in the
presence or absence of optimal concentrations (1000 mM) of the
IDO1-inhibitor, 1-methyl-L-tryptophan (Sigma-Aldrich).10,14 At
the end of the culture period, cells were collected and used for phe-
notypic and functional assays (see below). 
T-cell proliferation and in vitro suppression assays 
Standard mixed lymphocyte reactions were performed as pre-
viously described.23 Briefly, naive CD4+CD25– T cells (105/well)
were incubated for 5 days with 104/well irradiated (3000 cGy)
mature AML-DC in the presence or absence of 1-methyl-L-
tryptophan. The cells were then pulsed with 1 mCi (0.037 MBq)
per well of [3H]thymidine (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) and tested as previously described.23 The
stimulation index (SI) was calculated for each individual experi-
ment as follows: SI= cpm (counts per minute)(T-cell respon-
ders+stimulators)/cpm (T-cell responders). To test their suppres-
sive activity, purified CD4+CD25+ T cells (104/well), which had
been obtained after culture with AML-DC (see above), were
added to cultures consisting of the same donor-derived
CD4+CD25– T cells (105/well) as responders and irradiated allo-
geneic mononuclear cells as stimulators (104/well). After 5 days,
cultures were pulsed with 1 mCi per well of [3H]thymidine
(Amersham Pharmacia) and tested as previously described.21 To
test the capacity of AML-DC-induced CD4+CD25+ Treg to inhibit
the maturation of DC, normal immature DC were matured in
the presence of an optimal concentration of lipopolysaccharide
(Sigma-Aldrich; 1 mg/mL), as determined in preliminary experi-
ments, and highly purified CD4+CD25+ Treg, obtained after cul-
ture with AML-DC (DC:T cell=1:3). Purified CD4+CD25– T cells,
obtained from the same culture, were used as control samples.  
Generation of leukemic lysate and dendritic cell pulsing
AML cells were resolved in complete medium at a density of 107
cells/mL. Cells were treated with three cycles of heating and freez-
ing. Each cycle consisted of 10 min at 37°C followed by another
10 min at -80°C. After each cycle, the necrotic cell material was fil-
tered through an insulin syringe. At the end of the third cycle the
cell suspension was used as a soluble lysate and added to normal
immature DC at an AML:DC ratio of 2:1. After overnight incuba-
tion, pulsed DC were washed and matured. The endocytic activi-
ty of immature DC was assessed with PKH26 red fluorescent cell
linker kit (Sigma-Aldrich). Briefly, AML cells were washed twice
with RPMI without serum and antibiotics and resolved in diluent
C (106 cells in 200 mL). Diluted PKH26 was added to the AML cell
suspension v/v and incubated for 4 min in the dark. The reaction
was blocked with 10 mL RPMI 1640 supplemented with 10% fetal
calf serum for 4 min in the dark. After pulsing, DC were analyzed
using FACScan equipment (Becton Dickinson, Franklin Lakes, NJ,
USA). At least 10,000 events were collected in list mode on
FACScan software.
Inhibition of leukemia-reactive CD4+ T cells by 
regulatory T cells induced by leukemic dendritic cells 
Freshly purified CD3+ T cells, obtained from healthy donors,
were co-cultured in complete medium with irradiated (3000 cGy)
autologous DC, previously loaded with allogeneic necrotic AML
blasts, at a T cell:DC ratio of 10:1. During the priming phase, 20
U/ml IL-2 (Proleukin, Novartis, Basel, Switzerland) was added
every 2 days for 8 days. Then, every 8-10 days, T cells were re-
stimulated with AML-cell-loaded DC and IL-2 was added at day 2
after re-stimulation.  After three rounds of re-stimulation, T cells
were collected and used for functional suppression assays.
Cultured T cells were incubated with autologous normal DC, pre-
viously loaded or not with same patient’s AML lysate, in the pres-
ence or absence of AML-DC-induced Tregs (see above). 
Suppression of Wilms’ tumor-specific CD8+ T cells 
by autologous regulatory T cells induced 
by leukemic dendritic cells 
AML patients were preliminarily screened for HLA-A0201 pos-
itivity. AML-DC were pulsed or not with 10 mg/mL HLA-A0201-
restricted Wilms’ tumor (WT1)-derived peptide (PRIMM, Milan,
Italy; WT1 126-134) for 4 h in complete medium. Then, pulsed or
not pulsed AML-DC were cultured with 105 autologous CD3+ T
cells in 96-well, round-bottomed plates at a T cell:DC ratio of 10:1
in complete medium with 10% autologous serum supplemented
with recombinant human IL-15 (10 ng/mL; R&D Systems,
Minneapolis, MN, USA), IL-7 (5 ng/mL; Endogen) and IL-2 (20
U/mL; Proleukin) at day 2 and day 4. AML-DC-induced Tregs were
added or not to cell cultures at a 1:1 ratio with stimulating AML-
DC. According to the manufacturers’ instructions, T cells were
tested for antigen-specific intracellular interferon-g production
(FastImmune, CD8 Intracellular Cytokine Detection Kit; Becton
Dickinson) and for the frequency of WT1-specific CD8+ T cells
(Pro5® Recombinant Human MHC Pentamers; Proimmune,
Oxford, UK), after 24 h and 7 days of culture, respectively. 
Immunophenotype studies
Dual-color immunofluorescence was performed using the fol-
lowing panel of monoclonal antibodies: phycoerythrin (PE)- or flu-
orescein isothiocyanate (FITC)-conjugated anti-human CD3
(Pharmingen; clone UCHT1); PE-conjugated anti-human Foxp3
(Biolegend, San Diego, CA, USA; clone 259D); PE- or FITC-conju-
A. Curti et al.
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gated anti-human CD4 (Pharmingen; clone RPA-T4); PE- or FITC-
conjugated anti-human CD8 (Pharmingen; clone HIT8a); PE-con-
jugated anti-human CD25 (Pharmingen; clone M-A251); PE- or
FITC-conjugated anti-human HLA-DR (Pharmingen; clone L242).
PE- or FITC-conjugated antihuman CD1a (Biolegend; clone
HI149); PE- or FITC-conjugated antihuman CD86 (Biolegend;
clone IT2.2); PE-conjugated antihuman CD80 (Biolegend; clone
2D10); PE- or FITC-conjugated antihuman CD14 (Biolegend; clone
HCD14); FITC-conjugated antihuman CD83 (Biolegend; clone
HB15e); and FITC-conjugated antihuman CD40 (Biolegend; clone
HB14). Negative controls were isotype-matched irrelevant mono-
clonal antibodies (Pharmingen, Biolegend). Cells were analyzed by
using FACScan equipment (Becton Dickinson). At least 10000
events were collected in list mode on FACScan software.
Statistical analysis
Results are expressed as mean ± SD. Where indicated, differ-
ences were compared using Student’s t-test and χ2 analysis.
Results
Immature and mature leukemic dendritic cells 
express an active form of IDO1 protein
As previously reported,20 AML blasts can be differentiated
into AML-DC, maintaining leukemia-specific molecular
markers (Online Supplementary Figure S1), with a typical DC
morphology, high expression of HLA-DR, CD86, CD80,
CD40 and intermediate expression of CD1a and CD83. As
expected, the addition of maturation stimuli to day-6 AML-
DC (see Design and Methods) resulted in the up-regulation of
CD86, CD80, CD40 and CD83 levels, and in the down-
modulation of CD1a (Online Supplementary Figure S2). 
We previously demonstrated that a significant fraction
of AML blasts expresses IDO1 mRNA and protein.10,13
We, therefore, tested whether DC differentiation of
AML cells might influence IDO1 expression. As shown
in Figure 1A and B, DC differentiation of AML cells
resulted in a significant up-regulation of IDO1 both at
molecular and protein levels. IDO1 expression was not
influenced by AML lineage (Online Supplementary Table
S2). Interestingly, immature AML-DC also showed high
levels of IDO1 gene and protein although the levels were
lower than those of mature AML-DC. Moreover, both
baseline IDO1+ and IDO1– AML cells  gave rise to AML-
DC expressing IDO1 at high and comparable levels
(Figure 1C).
To test the enzymatic activity of IDO1 protein
expressed by AML-DC, the supernatants of cultured cells
were analyzed for L-kynurenine concentrations. As
shown in Figure 1D, IDO1 from AML-DC was active,
resulting in the increase of L-kynurenine in the culture
medium. This increase was more prominent in mature
AML-DC than in immature AML-DC, thus reflecting
higher mRNA and protein levels (Figure 1A and B). The
addition of the IDO1-inhibitor 1-methyl-L-tryptophan
resulted in a significant decrease of kynurenine production
by IDO1-expressing AML-DC. 
To test whether IDO1 expression by AML-DC results in
the inhibition of their ability to stimulate T-cell prolifera-
tion, IDO1-expressing mature AML-DC were used as
stimulators for allogeneic CD3+ T cells in a standard mixed
lymphocyte reaction in the presence or absence of 1-
methyl-L-tryptophan. As shown in Figure 1E, the addition
of 1-methyl-L-tryptophan resulted in a significant increase
of T-cell proliferation. Taken together, these data demon-
strate that both immature and mature AML-DC express
IDO1 at molecular and protein levels. The presence of
kynurenine in AML-DC cultures is strong evidence of
functional IDO1 activity, which is also supported by its
capacity to inhibit T-cell proliferation.
Leukemic DC induce Treg
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Figure 1. AML-DC express a function-
ally active IDO1 protein. (A) Real-
time quantitative polymerase chain
reaction of IDO1 mRNA in AML
blasts and after differentiation into
DC (immature AML-DC, mature AML-
DC). Results represent the mean ±
SD of eight different experiments.
(B) Western blot analysis of IDO1
protein. Lanes are as following: 1)
IDO1- AML blasts; 2) immature AML-
DC; 3) mature AML-DC. The results
are representative of six different
experiments. (C) Real-time quantita-
tive polymerase chain reaction of
IDO1 mRNA in IDO1+ and IDO1– AML
samples before and after differentia-
tion to DC. The results are the mean
± SD of six different experiments. (D)
L-kynurenine production of AML
blasts and AML-DC at different
stages of maturation. The results are
the mean ± SD of six different exper-
iments. AML blasts include IDO1–
and IDO1+ AML samples. (E)
Allogeneic T-cell proliferation
induced by AML blasts and AML-DC
in the presence and absence of 1-
methyl tryptophan (1-MT) (1000
mM). The results are the mean ± SD
of six different experiments. 
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IDO1-expressing leukemic dendritic cells increase
CD4+CD25+Foxp3+ T cells
We previously demonstrated that IDO1-expressing
AML samples induce a population of fully functional
CD4+CD25+Foxp3+ Treg by conversion from the
CD4+CD25+ T-cell fraction.14 To investigate the role of
IDO1 expression by AML-DC on Treg-development, we
co-cultured IDO1-expressing AML-DC with highly puri-
fied allogeneic CD3+ T cells, obtained from healthy
donors, in the presence or absence of 1-methyl-L-
tryptophan. The viability of cells cultured in the pres-
ence of 1-methyl-L-tryptophan was not different from
that of cells cultured in medium alone (79%±7 and
85%±8, respectively); furthermore, CD4+ and CD8+ T-
cell frequencies were not modified by the addition of 1-
methyl-L-tryptophan (data not shown). Co-culture of T
cells with IDO1-expressing AML-DC increased the per-
centage of CD4+CD25+ T cells (Figure 2A, P<0.01) and
the surface expression of CD25 (mean fluorescence
intensity [MFI] 150±45 and 980±390 before and after co-
culture, respectively; P=0.0003). Moreover, CD4+CD25+
T cells collected after culture with IDO1-expressing
AML-DC had an increased percentage of Foxp3+ cells, as
compared to baseline (Figure 2B, P<0.01). These data are
similar to those obtained with normal IDO1-expressing
monocyte-derived DC, which have recently been shown
to induce, in vitro, Foxp3+ T cells.7,8 This phenotypic pat-
tern suggests that CD4+ T lymphocytes, after co-culture
with IDO1-expressing AML-DC, acquire a CD4+CD25+
Treg phenotype. Importantly, the addition of 1-methyl-L-
tryptophan to co-cultures of T cells with IDO1-express-
ing AML-DC completely restored the expression of
CD25 and Foxp3 to that observed before culture (Figure
2A and B). This finding strongly suggests that IDO1 rep-
resents the main mechanism by which AML-DC induce
CD4+CD25+Foxp3+ T cells.
Leukemic dendritic cell-induced CD4+CD25+
T cells have regulatory activity
An additional set of functional experiments was per-
formed to validate  the Treg nature of the cells induced by
IDO1-expressing AML-DC. Naive CD4+CD25– T cells
were stimulated by allogeneic mononuclear cells in the
presence of AML-DC-cultured T cells. As shown in Figure
3, T-cell proliferation was significantly reduced when
AML-DC-cultured CD4+CD25+ T cells were added to cell
cultures (P<0.03). No effect was observed when naïve T
cells were added to cell cultures (data not shown). These
data support the hypothesis that CD4+CD25+Foxp3+ T
cells induced by IDO1-expressing AML-DC retain
immunosuppressive activity and may be considered bona
fide Treg.
Regulatory T cells induced by IDO1-expressing
leukemic dendritic cells inhibit the proliferation 
of autologous leukemia-specific CD4+ T cells
To test the ability of AML-DC-induced Treg to inhibit
the leukemia-specific immune response, we first induced
a population of T cells, obtained from healthy donors,
with reactivity against leukemia cells. Immature DC were
loaded with necrotic AML blasts and then, after matura-
tion, used as stimulators for autologous total CD3+ T
cells. As shown in Figure 4A, immature DC were capable
of internalizing necrotic leukemia cells. Moreover,
leukemia cell-loaded DC showed increased allostimulato-
ry capacity of T-cell proliferation as compared to
unloaded DC (data not shown). At the end of the culture,
the proliferation of total CD3+ T cells, as well as that of
fractionated CD4+ and CD8+ T cells, was tested in a sec-
ondary mixed lymphocyte reaction against DC, which
had been pulsed with the same leukemia cells used for T-
cell stimulation. Unloaded DC were used as negative con-
trols. As shown in Figure 4B, only CD4+, but not CD8+ T
cells proliferated specifically in response to leukemia cell-
loaded DC (P<0.01). Indeed, CD3+, CD4+ and CD8+ cells
gave 2603±951, 677±271 and 435±118 cpm in response to
not pulsed DC and 3073±1028, 1299±556 and 635±240
cpm in response to pulsed DC, respectively. Thus, further
experiments were performed with CD4+ T cells obtained
after culture with leukemia cell-loaded DC. In particular,
AML-DC-induced Treg were added to a mixed lympho-
cyte reaction consisting of leukemia-reactive CD4+ T cells
as responders and autologous leukemia cell-loaded DC as
stimulators. As shown in Figure 4C, AML-DC-induced
Treg significantly reduced leukemia-specific CD4+ T cell-
proliferation (P<0.01; 471±206 versus 1299±556 cpm).
This effect was dose-dependent (data not shown) and
blocked by anti-HLA-class II antibody (Online
Supplementary Figure S3). These data demonstrate that
IDO1-expressing AML-DC may induce a population of
Treg which is capable of inhibiting the proliferation of
leukemia-specific CD4+ T cells. 
A. Curti et al.
2026 haematologica | 2010; 95(12)
Figure 2. IDO1-expressing AML-DC induce CD4+CD25+Foxp3+ T cells.
Phenotypic analysis of CD3+ T cells cultured for 7 days in the pres-
ence of mature AML-DC with or without the addition of 1-methyl
tryptophan (1-MT) (1000 mM). The results are expressed as percent-
age of positive cells. The results are the mean ± SD of five different
experiments. 
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Regulatory T cells induced by IDO1-expressing
leukemic dendritic cells impairs the generation 
of antigen-specific CD8+ T cells
WT1 has recently been demonstrated to be over-
expressed in the vast majority of AML samples and may
be used as a leukemia target antigen given its immuno-
genicity.25 In the attempt to reproduce a model of anti-
leukemia vaccination in vitro, AML-DC were used to
induce a population of autologous WT1-specific CD8+ T
cells in the presence of IL-15, IL-7 and IL-2. To test the
capacity of Treg induced by AML-DC to reduce the gener-
ation of antigen-specific CD8+ T cells, WT1-specific T cells
were stimulated by antigen-loaded AML-DC in the pres-
ence or absence of autologous Treg induced by AML-DC.
As shown in Figure 5A and B, AML-DC were highly effi-
cient in stimulating IFN-g-secreting and WT1-specific
CD8+ T cells. This effect was more prominent when the
stimulating AML-DC were loaded with WT1-derived
peptide. Interestingly, the addition of AML-DC-induced
Treg to cell cultures resulted in a significant reduction of
interferon-g-secreting and WT1-specific CD8+ T cells to
levels which were comparable to those of the negative
control samples.  Hence, Treg expanded by IDO1-express-
ing AML-DC significantly suppressed the development of
leukemia antigen-specific CD8+ T cells.
Regulatory T cells induced by IDO1-expressing
leukemic dendritic cells impair the full maturation 
of normal dendritic cells 
To test the capacity of AML-DC-induced CD4+CD25+
Treg to inhibit the maturation of DC, normal immature DC
were matured in the presence of an optimal concentration
of lipopolysaccharide and with the addition of highly puri-
fied CD4+CD25+ Treg, obtained after culture with AML-
DC. Purified CD4+CD25– T cells, obtained from the same
culture, were used as control samples. As expected, addi-
tion of lipopolysaccharide resulted in marked increases of
CD80, CD86, CD40 and CD83 on the surface of the DC,
as evaluated both as percentage of positive cells and as
mean fluorescence intensity (data not shown). As shown in
Figure 6, the addition of Treg significantly inhibited the
maturation of DC by reducing the expression of matura-
tion-related markers on DC. These data suggest that Treg
induced by AML-DC may have a tolerogenic effect also
through the inhibition of the complete maturation of nor-
mal DC. 
Discussion
The demonstration that AML cells can be differentiated
in vitro into DC-like cells has provided a new tool for anti-
leukemia vaccination.19 The rationale relies on the concept
that ex-vivo differentiation of AML blasts to DC has the
advantage of obtaining antigen-presenting cells in the
absence of in-vivo acting immunosuppressive factors.
However, we previously demonstrated that a significant
portion of AML-DC have impaired IL-12 production and
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Figure 3. AML-DC-induced CD4+CD25+ T cells act as Treg by inhibiting
allogeneic T-cell proliferation. Naive CD4+CD25– T cells were stimu-
lated to proliferate by allogeneic mononuclear cells (MNC) in the
presence or absence of AML-DC-cultured CD4+CD25+ T cells. The
results are mean ± SD of three different experiments.
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Figure 4. Treg induced by IDO1-expressing AML-DC inhibit leukemia-
specific T-cell proliferation. (A) AML cells were lysed and used for the
pulsing of immature normal monocyte-derived DC. The endocytic
activity of immature DC was assessed with a PKH26 red fluorescent
cell linker kit. Pulsed and not pulsed DC were tested by flow cytom-
etry. The results are representative of three different experiments.
(B) Freshly purified normal CD3+ T cells were co-cultured with autol-
ogous DC, previously loaded with allogeneic necrotic AML blasts, at
a 10:1 T cell–to–DC cell ratio. After three rounds of re-stimulation, T
cells were collected, purified into different T-cell subsets and used
for proliferation assays in response to autologous monocyte-derived
DC previously loaded with necrotic AML blasts. As control samples,
unloaded monocyte-derived DC were used. AML cells used for DC
pulsing were the same cells as those with had been used to gener-
ate AML-DC. The results are the mean ± SD of four different exper-
iments. (C) Tregs induced by IDO1-expressing AML-DC were added to
cultures consisting of leukemia-specific CD4+ T cells and autologous
DC previously loaded with necrotic AML cells. The results are the
mean ± SD of three different experiments.
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are not capable of contrasting the inhibitory effect of the
leukemic microenvironment on T cells.20 Moreover, in
AML patients, circulating DC belonging to the leukemic
clone had impaired functional capacity26 and induced
apoptosis of tumor-specific T cells by a Fas-FasL interac-
tion.27 These data suggest that leukemic DC from AML
patients retain some immunosuppressive features and
may contribute to leukemia escape from immune control. 
The role of IDO1 in the induction of immunological tol-
erance has been extensively studied.28 Normal DC have
the capacity to modulate IDO1 expression in response to
external pro-inflammatory stimuli, such as interferon-g,29-32
and the interaction of DC with CTLA-4-expressing Treg is
known to up-regulate a tolerogenic pathway, including
IDO1 expression.33,34 Moreover, recent studies have also
demonstrated that certain subsets of human myeloid DC
might constitutively express IDO1 protein.35,36 These data
highlight the physiological existence of a subset of normal
regulatory DC, which are functionally defined by the
expression, either constitutive or inducible, of IDO1 pro-
tein (IDO1+DC). In this study, we show that leukemic DC
may represent another example of IDO1-expressing DC.
We and others10-13 have previously demonstrated that a
subset of AML samples from newly diagnosed patients
constitutively expresses significant amounts of IDO1 gene
and protein. Our current results demonstrate that during
DC generation IDO1 expression is markedly induced/up-
regulated in all AML samples. Interestingly, both imma-
ture and mature AML-DC express IDO1, although the
expression is greater in the later stage of differentiation.
These data are partially in contrast to those obtained from
normal myeloid DC, in which it is known that IDO1 lev-
els increase significantly only after maturation.7,8 It
remains to be elucidated whether this difference derives
from the leukemic origin of AML-DC as the result of
leukemia-derived molecular alterations of the IDO1 path-
way.
Tumor cells, including leukemia cells, are known to cre-
ate an inhibitory microenvironment for the immune sys-
tem.37 Among the different mechanisms by which tumor
cells escape the immune control, the induction of Treg is
emerging as a very important one. A significantly
increased number of Tregs has been observed in several
tumors, such as lung, breast, pancreatic, and ovarian carci-
nomas, and melanoma, and Treg have been found to sup-
press tumor-specific immune responses.38-40 In hematologic
malignancies, an increase in circulating CD4+CD25+ Treg
has been demonstrated in Hodgkin’s and non-Hodgkin’s
lymphomas, chronic lymphocytic leukemia, AML, multi-
ple myeloma and high-risk myelodysplastic syndromes.41-
46 In particular, we demonstrated that AML cells favor the
de novo emergence of a population of Tregs through the aber-
rant over-expression of IDO1 protein.14 In the present
study, we show that IDO1-expressing AML-DC expand,
in vitro, a population of CD4+CD25+ Foxp3+ T cells which
act as bona fide Treg cells. These data are in agreement with
recent reports that, both in mice and humans, tryptophan
catabolism by normal DC mediates the emergence of
CD25+Foxp3+ Treg cells by conversion from CD25–Foxp3–
cells.4-6 Our observations in leukemic DC support the
notion that IDO1 expression may be considered a general
tolerogenic pathway by which normal and malignant DC
suppress T-cell-mediated immune responses through the
induction of Treg. 
Since AML-DC have been proposed as a means of active
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Figure 5. Treg induced by IDO1-expressing AML-DC inhibit the WT1-
specific CD8 T-cell response. AML-DC were pulsed or not with 10
mg/mL HLA-A0201-restricted WT1 126-134 for 4 h in complete
medium. Then, pulsed or not pulsed AML-DC were cultured with 105
autologous CD3+ T cells at a ratio of 10:1 (T:DC) with 10% autolo-
gous serum supplemented with IL-15, IL-7 and IL-2. AML-DC-
induced Treg were added or not to cell cultures at a 1:1 ratio with
stimulating AML-DC. (A) CD8+ T cells were tested for WT1-specific
intracellular interferon-g production after 24 h of culture. (B) CD8+ T
cells were tested for the frequency of WT1-specific CD8+ T cells, by
using recombinant human MHC pentamers, after 7 days of culture.
Results are representative of three independent experiments.
Figure 6. Treg induced by IDO1-expressing AML-DC inhibit the full
maturation of normal monocyte-derived DC. Normal immature
monocyte-derived DC were matured in the presence of an optimal
concentration of lipopolysaccharide (1 mg/mL) and CD4+CD25+ Tregs,
obtained after culture with AML-DC and highly purified. As control
samples, purified CD4+CD25– T cells, obtained from the same cul-
ture, were used. Surface expression of maturation-related markers
was tested on DC and expressed as the percentage of positive cells.
Results are representative of three independent experiments.
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immunotherapy,19 our results have some clinical implica-
tions. The initiation of a T-cell immune response depends
strictly on the balance between different activating or
inhibiting pathways, which act during DC/T cell encoun-
ters. Mature AML-DC, with their high expression of co-
stimulatory molecules, have been shown to have better
antigen-presenting capacity than that of undifferentiated
AML cells or immature AML-DC.15-18 In line with these
data, the results of our study clearly demonstrate that
AML-DC are highly efficient at inducing a CD8+ T-cell
response, which is specific for the leukemia-associated
antigen, WT1. However, our results demonstrate that,
through the expression of IDO1, AML-DC may also
induce a population of CD4+CD25+Foxp3+ Treg, which are
capable of suppressing allogeneic T-cell proliferation and,
in the autologous setting, of inhibiting both CD4 and CD8
T-cell functions in response to leukemia-specific antigens,
including WT1. Moreover, our data suggest that Treg
induced by IDO1-expressing AML-DC inhibit the matura-
tion of normal DC, which in turn may have a decreased
antigen-presenting capacity. Altogether, these findings
indicate that Treg which are induced by IDO1-expressing
AML-DC may play their tolerogenic role at different levels
during the induction of a leukemia-specific immune
response. In particular, Treg may inhibit the direct priming
of T cells by negatively affecting their capacity to prolifer-
ate/expand in response to leukemia-associated antigens
and they may impair the cross-priming of T cells by sup-
pressing the full maturation of normal DC, thus resulting
in impaired antigen presentation. Indeed, although AML-
DC have the potential to elicit leukemia-specific immuni-
ty by expanding the frequencies of the antigen-specific T-
cell repertoire, the use of IDO1-expressing AML-DC as
part of a cellular vaccine against leukemia may be ham-
pered by the consensual activation/expansion of a popula-
tion of suppressive Treg, which are well-known to reduce
the efficacy of vaccination strategies.47
In summary, our study demonstrates that: (i) AML-DC
invariably express IDO1 gene and protein, which is enzy-
matically and functionally active; (ii) AML-DC are capable
of inducing a population of Treg through IDO1; and (iii) Treg
which are induced by AML-DC act as suppressors both by
inhibiting a leukemia-specific T-cell immune response and
by reducing the antigen-presenting capacity of normal
DC. These results have clinical implications as they
demonstrate a novel  immunological tumor escape mech-
anism for AML, in vivo, and question the use of AML-DC
as an anti-leukemia vaccine.
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